- Conditions
- Growth Hormone Deficiency
- Interventions
- Recombinant Human Growth Hormone, Recombinant Human IGF-1
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 25 Years to 65 Years · Male only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–10
of 10
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Anorexia Nervosa
- Interventions
- RhIGF-1
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 12 Years to 18 Years · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Rett Syndrome
- Interventions
- Recombinant Human Insulin Growth Factor 1 (rhIGF-1), Placebo
- Drug
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 2 Years to 10 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Insulin-Like Growth Factor-1 Deficiency, Growth Disorders
- Interventions
- rhIGF-1 (mecasermin) for a period of 86 weeks
- Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 3 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Brisbane, California
- Conditions
- Cystic Fibrosis
- Interventions
- recombinant human IGF-1, Placebo
- Drug
- Lead sponsor
- Stony Brook University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Stony Brook, New York
- Conditions
- Noonan Syndrome
- Interventions
- rhIGF-1/rhIGFBP-3
- Drug
- Lead sponsor
- Insmed Incorporated
- Industry
- Eligibility
- 2 Years to 16 Years
- Enrollment
- 24 participants
- U.S. locations
- 2
- States / cities
- New Hyde Park, New York • Columbus, Ohio
- Conditions
- Disorder of Bone Density and Structure, Unspecified
- Interventions
- Recombinant human insulin like growth factor-1 (rhIGF-1)
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 12 Years to 26 Years · Female only
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Growth Hormone Insensitivity Syndrome
- Interventions
- mecasermin
- Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1991 – 2011
- U.S. locations
- 1
- States / cities
- Brisbane, California
- Conditions
- Insulin-like Growth Factor-1 Deficiency
- Interventions
- NutropinAq® (Somatropin [rDNA origin]), Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])
- Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Brisbane, California
- Conditions
- Growth Disorders, Insulin-Like Growth Factor-1 Deficiency
- Interventions
- rhIGF-1 (mecasermin, Tercica, Inc.)
- Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 3 Years to 12 Years
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Brisbane, California